therapeuticsmd - TXMD

TXMD

Close Chg Chg %
2.00 0.00 0.00%

Closed Market

2.00

0.00 (0.00%)

Volume: 16.09K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Company Overview: therapeuticsmd - TXMD

TXMD Key Data

Open

$2.00

Day Range

1.94 - 2.03

52 Week Range

0.84 - 2.94

Market Cap

$23.15M

Shares Outstanding

11.57M

Public Float

11.39M

Beta

0.56

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.05

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

22.75K

 

TXMD Performance

1 Week
 
-4.76%
 
1 Month
 
-11.11%
 
3 Months
 
21.21%
 
1 Year
 
126.19%
 
5 Years
 
-97.12%
 

TXMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About therapeuticsmd - TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

TXMD At a Glance

TherapeuticsMD, Inc.
951 Yamato Road
Boca Raton, Florida 33431
Phone 1-561-961-1900 Revenue 3.02M
Industry Pharmaceuticals: Major Net Income -569,000.00
Sector Health Technology 2025 Sales Growth 71.607%
Fiscal Year-end 12 / 2026 Employees 1
View SEC Filings

TXMD Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 6.24
Price to Book Ratio 0.702
Price to Cash Flow Ratio 7.78
Enterprise Value to EBITDA -5.783
Enterprise Value to Sales 5.781
Total Debt to Enterprise Value 0.349

TXMD Efficiency

Revenue/Employee 3,022,000.00
Income Per Employee -569,000.00
Receivables Turnover 0.857
Total Asset Turnover 0.079

TXMD Liquidity

Current Ratio 2.531
Quick Ratio 2.531
Cash Ratio 1.564

TXMD Profitability

Gross Margin 60.523
Operating Margin -139.444
Pretax Margin -21.608
Net Margin -18.829
Return on Assets -1.708
Return on Equity -2.408
Return on Total Capital -1.98
Return on Invested Capital -2.012

TXMD Capital Structure

Total Debt to Total Equity 22.686
Total Debt to Total Capital 18.491
Total Debt to Total Assets 16.191
Long-Term Debt to Equity 19.058
Long-Term Debt to Total Capital 15.534
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Therapeuticsmd - TXMD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
69.96M 1.30M 1.76M 3.02M
Sales Growth
-19.54% -98.14% +35.25% +71.61%
Cost of Goods Sold (COGS) incl D&A
1.40M 922.00K 509.00K 1.19M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.19M 922.00K 509.00K 1.19M
Depreciation
- 600.00K 100.00K 809.00K
Amortization of Intangibles
593.00K 822.00K 509.00K 384.00K
COGS Growth
-92.58% -34.00% -44.79% +134.38%
Gross Income
68.57M 380.00K 1.25M 1.83M
Gross Income Growth
+0.67% -99.45% +229.47% +46.09%
Gross Profit Margin
+98.00% +29.19% +71.10% +60.52%
2022 2023 2024 2025 5-year trend
SG&A Expense
57.90M 8.90M 4.74M 6.04M
Research & Development
- - - -
-
Other SG&A
57.90M 8.90M 4.74M 6.04M
SGA Growth
-72.15% -84.62% -46.71% +27.38%
Other Operating Expense
- - - -
-
Unusual Expense
- 9.47M 1.27M 176.00K
EBIT after Unusual Expense
1.19M (8.52M) (4.76M) (4.39M)
Non Operating Income/Expense
(117.00K) 981.00K 2.43M 3.75M
Non-Operating Interest Income
- 300.00K 144.90K 150.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 200.00K 9.50K 8.00K
Interest Expense Growth
- -100.00% -95.25% -15.79%
Gross Interest Expense
- 200.00K 9.50K 8.00K
Interest Capitalized
- - - -
-
Pretax Income
1.07M (7.74M) (2.34M) (653.00K)
Pretax Income Growth
+100.62% -820.86% +69.74% +72.13%
Pretax Margin
+1.54% -594.62% -133.05% -21.61%
Income Tax
- - (43.00K) (31.00K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.07M (7.70M) (2.31M) (653.00K)
Minority Interest Expense
- - - -
-
Net Income
1.07M (7.70M) (2.31M) (653.00K)
Net Income Growth
+100.62% -816.85% +69.97% +71.76%
Net Margin Growth
+1.54% -591.32% -131.29% -21.61%
Extraordinaries & Discontinued Operations
(94.49M) (2.58M) 131.00K 84.00K
Discontinued Operations
(94.49M) (2.58M) 131.00K 84.00K
Net Income After Extraordinaries
(93.42M) (10.28M) (2.18M) (569.00K)
Preferred Dividends
- - - -
-
Net Income Available to Common
(93.42M) (10.28M) (2.18M) (569.00K)
EPS (Basic)
-10.3476 -0.9844 -0.1891 -0.0492
EPS (Basic) Growth
+52.23% +90.49% +80.79% +73.98%
Basic Shares Outstanding
9.03M 10.44M 11.53M 11.57M
EPS (Diluted)
-10.3476 -0.9844 -0.1891 -0.0492
EPS (Diluted) Growth
+52.23% +90.49% +80.79% +73.98%
Diluted Shares Outstanding
9.03M 10.44M 11.53M 11.57M
EBITDA
11.86M (7.60M) (2.98M) (3.02M)
EBITDA Growth
+108.74% -164.11% +60.76% -1.27%
EBITDA Margin
+16.95% -583.79% -169.39% -99.97%

Insider Actions for Therapeuticsmd - TXMD

Date Name Shares Transaction Value
Apr 15, 2025 Tommy George Thompson Director 14,779 Open market or private purchase of non-derivative security Non-derivative transaction at $1 per share 14,779.00
Apr 15, 2025 Marlan D. Walker Chief Executive Officer 73,639 Open market or private purchase of non-derivative security Non-derivative transaction at $1 per share 73,639.00

Therapeuticsmd in the News